Supplements
2019
*December 2019
CHALLENGING THE STATUS QUO IN DME
*October 2019 - Supplement 2
OPTIMIZING TREATMENT OF nAMD
*October 2019 - Supplement 1
Surgical Technique Supplement Editorial
*June 2019 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg as Initial Therapy in Pseudophakic Patients With Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Noninfectious Posterior Segment Uveitis
*March 2019 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
Retina
2018
*November 2018 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
CASES IN REFINING MANAGEMENT OF DIABETIC MACULAR EDEMA
*October 2018 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
Melanocortin in the Pathogenesis of Inflammatory Eye Diseases: Considerations for Treatment
*September 2018 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
DUKE ADVANCED VITREOUS SURGERY COURSE AND THE DUKE FELLOWS ADVANCED VITREOUS SURGERY COURSE
*June 2018 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
OZURDEX® (dexamethasone intravitreal implant) 0.7 mg for Treating Inflammation in Macular Edema Following Retinal Vein Occlusion: A Case-Based Discussion
*Feburary 2018 (Sponsored, non-peer-reviewed monograph mailed with RETINA)
Tribute to Jerry A. Shields, MD
*January 2018 (Peer-reviewed Proceedings)
MacTel Project: Selected Proceedings Sponsored by The Lowy Medical Research Institute
*January 2018 (Sponsored, non-peer review monograph mailed with RETINA)
Melanocortin Receptors and Their Role in Noninfectious Uveitis: An Expert Panel Discussion
2017
*December 2017 (Sponsored, non-peer reviewed monograph mailed with RETINA)
Chronic Noninfectious Uveitis of the Posterier Segment
*July 2017 (Sponsored, non-peer reviewed monograph mailed with
RETINA)
OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg for Use in Noninfectious Posterior Segment Uveitis: A Case-Based Discussion
2016
*December 2016
The International Retinal Imaging Symposium (IRIS IV) 2016
The International Retinal Imaging Symposium (IRIS) convenes on an annual basis and brings together experts in this field from all over the world to speak on the newest technologies and innovations in retinal imaging.
2015
EXPERT CASE DISCUSSIONS IN DIABETIC RETINOPATHY: Multidisciplinary Considerations
This continuing medical education activity is jointly provided by Wills Eye Hospital and MedEdicus LLC. This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
NEW FRONTIERS IN THE MANAGEMENT OF NONINFECTIOUS UVEITIS INVOLVING THE POSTERIOR SEGMENT
This continuing medical education activity is jointly provided by New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC and is supported through an unrestricted educational grant from Santen Pharmaceutical Co, Ltd.
NEW FRONTIERS IN THE TREATMENT OF DIABETIC MACULAR EDEMA
This continuing medical education activity is jointly provided by Wills Eye Hospital and MedEdicus LLC and is supported through an unrestricted educational grant from Aerpio Therapeutics.
GLOBAL DEVELOPMENTS AND APPROACHES IN THE TREATMENT OF CHRONIC NONINFECTIOUS POSTERIOR UVEITIS: HIGHLIGHTS FROM AN EXPERT ROUNDTABLE DISCUSSION
Jointly provided by New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. This continuing medical education activity is supported through an unrestricted educational grant from Santen Pharmaceutical Co, Ltd.
CURRENT MANAGEMENT OF DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY: A MULTIDISCIPLINARY DISCUSSION OF CLINICAL CASES
Jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and MedEdicus LLC. This continuing education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
2014
INTRAVITREAL INJECTION TECHNIQUE AND MONITORING: UPDATED GUIDELINES OF AN EXPERT PANEL
This supplement was paid for through the use of advertising support by Genentech. Genentech has had no prior input in the consensus meeting or preparation of this document in any way.
REAL-WORLD EXPERIENCE AND RESHAPING THE VMA TREATMENT PARADIGM FOR OPTIMAL OUTCOMES: EXPERT PERSPECTIVES
Jointly provided by Wills Eye Hospital and MedEdicus LLC. This continuing education activity is supported through an unrestricted educational grant from ThromboGenics NV.
INDIVIDUALIZING THERAPY FOR PATIENTS WITH NEOVASCULAR AMD AND DME: CONSIDERATIONS FOR SHORT- AND LONG-TERM MANAGEMENT
Proceedings from an Experts Roundtable Discussion. Jointly sponsored by The University of Louisville Department of Continuing Education and MedEdicus. This continuing education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
MACULAR EDEMA FOLLOWING CENTRAL RETINAL VEIN OCCLUSION (CRVO): THE ROLE OF EYLEA® (AFLIBERCEPT) INJECTION
Supplement prepared and sponsored by Regeneron.
2013
CYTOKINE TRAP TECHNOLOGY AND NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION: THE ROLE OF EYLEA (AFLIBERCEPT) INJECTION
Prepared and sponsored by Regeneron
CASE DEBATES IN THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA
Jointly sponsored by The New York Eye and Ear Infirmary and MedEdicus LLC.
Supported through an unrestricted educational grant from Genentech, Inc.
REFINING ANTI-VEGF DOSING STRATEGIES FOR YOUR PATIENTS WITH WET AMD
Jointly sponsored by The New York Eye and Ear Infirmary and MedEdicus LLC.
Supported through an unrestricted educational grant from Genentech, Inc.
2012
VITREOMACULAR DISORDERS: PATHOGENESIS AND TREATMENT
Proceedings from a Roundtable Symposium
Supported through an unrestricted educational grant from ThromboGenics, Inc.
pp. S173-S232
MANAGEMENT OF DIABETIC MACULAR EDEMA APPLICATION OF CURRENT EVIDENCE TO PATIENT CARE
Highlights from a Roundtable Discussion
Supported through an unrestricted educational grant from Alimera Sciences.
*
May 2012 (Monograph mailed with
RETINA)
ADVANCES IN THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION
Proceedings from a Roundtable Discussion
Jointly sponsored by The New York Eye and Ear Infirmary and MedEdicus LLC.
Supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc, with additional support from Optovue, Inc.
TRIBUTE TO LARRY A. YANNUZZI, MD
pp. OP-893:OP-906,1-1572,S1-S28
